Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2006

View Archived Issues

Vical begins phase II study of DNA vaccine against CMV

Dr. Reddy's and Argenta collaborate on novel treatment for COPD

Avantogen and Innovate Oncology merge key oncology program

Altea and Teikoku Seiyaku sign Parkinson's transdermal patch agreement in Japan

Samaritan inlicenses drugs for mitochondrial disorders

Levulan BLU-U reduces acne lesions in phase II study

Elan updates progress

Antitumor and antiangiogenic potential of the phytochemical sulforaphane

In vitro and in vivo anticancer activity of KP-772

Targeting bombesin/GRP receptor pathways for sepsis

Enrollment completed in phase III chronic low back pain study of bicifadine

Halozyme begins study of subcutaneous morphine with Hylenex

Chromos Molecular Systems acquires Targeted Molecules

InterMune discontinues Actimmune ovarian cancer study

Zactima granted fast track designation for medullary thyroid carcinoma

Acuity studies Cand5 for wet AMD and diabetic macular edema

Ecopia cleared for Canadian phase I study of ECO-4601 in cancer patients

IND approved for phase I study of abiraterone acetate in advanced prostate cancer

Additional clinical responses seen in phase II talabostat studies

Androxal may restore normal testosterone level in testosterone deficient men

RotaTeq receives FDA approval

Recent Japan Tobacco patents disclose novel analgesic agents

Novel therapeutics for neurological disorders reported in recent patent literature

High intake of antioxidants may reduce the risk of AMD

Angiotensin II receptor antagonists evaluated for the treatment of hepatic fibrosis

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...